Yildirim Sinan, Aslan Onur
Department of Emergency Medicine, Canakkale Mehmet Akif Ersoy State Hospital, Canakkale, Turkey.
Department of Cardiology, Tarsus State Hospital, Mersin, Turkey.
Heliyon. 2023 Aug 12;9(8):e19079. doi: 10.1016/j.heliyon.2023.e19079. eCollection 2023 Aug.
Major bleeding in the treatment of atrial fibrillation is closely associated with an increased risk of death and major adverse outcomes in both the short and long term, but all bleeding events are associated with a reduced quality of life. Bleeding events are also known to reduce medication adherence. In this sense, bleeding risk scores are important tools to help predict major bleeding. However, it is not clear which scoring system is superior.
In this study, our aim was to compare bleeding risk scores and to examine the factors associated with bleeding in patients with major bleeding while using vitamin K antagonists.
In this retrospective and single-center study, scoring, laboratory and demographic data were analyzed with SPSS 20.0 statistical program.
The mean age of a total of 1434 patients included in our study was 68.2 ± 11.3 years, range was 39-93 years and 769 (53.6%) of these patients were male. Of 588 patients with major bleeding, 93 (15.8%) had intracranial hemorrhage. Logistic regression analysis comparing the scoring systems among themselves revealed that the GARFIELD-AF scoring system had a predictive effect on major bleeding independent of the effect of other scoring systems (OR: 1.532, 95% CI 1.348-1.741, p < 0.001). The area under the curve (AUC) for GARFIELD-AF was 0.690 (0.662-0.718) as a result of the ROC analysis considering the best cut-off point of 3.2% calculated for 2 years. AUC 0.659 (0.630-0.687) for HAS-BLED, AUC 0.636 (0.606-0.665) for ORBIT and AUC 0.611 (0.5810.642) for ATRIA. When we compare the patient group with the control group, it can be said that intracranial hemorrhage occurred independently of INR and TTR values, unlike in the major bleeding group (p:0.129, p:0.545).
In patients using vitamin K antagonists for atrial fibrillation, the GARFIELD-AF risk score was found to be superior to important bleeding risk scores such as HAS-BLED, ORBIT and ATRIA in terms of predicting major bleeding. It is an important result that intracranial hemorrhages, which have a special place among major hemorrhages, were independent of INR and TTR levels. It is noteworthy that 8.2% of patients with major bleeding had a history of minor bleeding in the last year.
心房颤动治疗中的大出血与短期和长期死亡风险及主要不良结局增加密切相关,但所有出血事件均与生活质量下降有关。已知出血事件还会降低药物依从性。从这个意义上讲,出血风险评分是帮助预测大出血的重要工具。然而,尚不清楚哪种评分系统更优越。
在本研究中,我们的目的是比较出血风险评分,并研究在使用维生素K拮抗剂的大出血患者中与出血相关的因素。
在这项回顾性单中心研究中,使用SPSS 20.0统计程序分析评分、实验室和人口统计学数据。
我们研究纳入的1434例患者的平均年龄为68.2±11.3岁,年龄范围为39 - 93岁,其中769例(53.6%)为男性。在588例大出血患者中,93例(15.8%)发生了颅内出血。对评分系统进行相互比较的逻辑回归分析显示,GARFIELD - AF评分系统对大出血具有独立于其他评分系统影响的预测作用(OR:1.532,95%CI 1.348 - 1.741,p < 0.001)。考虑到计算出的2年最佳切点为3.2%,通过ROC分析得出GARFIELD - AF的曲线下面积(AUC)为0.69(0.662 - 0.718)。HAS - BLED的AUC为0.659(0.630 - 0.687),ORBIT的AUC为0.636(0.606 - 0.665),ATRIA的AUC为0.611(0.581 - 0.642)。当我们将患者组与对照组进行比较时,可以说与大出血组不同,颅内出血的发生与INR和TTR值无关(p:0.129,p:0.545)。
在使用维生素K拮抗剂治疗心房颤动的患者中,发现GARFIELD - AF风险评分在预测大出血方面优于HAS - BLED、ORBIT和ATRIA等重要出血风险评分。在大出血中占有特殊地位的颅内出血与INR和TTR水平无关,这是一个重要结果。值得注意的是,8.2%的大出血患者在过去一年有小出血史。